Moderna to present early Phase 1/2 data on multiplexed mRNA cancer therapy at ASH 2026
Moderna announced that initial results from its Phase 1/2 MyEngage trial of mRNA‑2808, a multiplexed mRNA drug targeting three myeloma antigens, will be shown at the American Society of Hematology meeting in December 2026. Twelve heavily pre‑treated patients have been dosed, and among the 11 patients whose response could be evaluated, four showed tumor shrinkage (two very good partial responses and two partial responses). No dose‑limiting toxicities or treatment‑related serious adverse events were reported, although five patients experienced mild cytokine release syndrome and 41.7% had grade‑3 or higher adverse events, mainly blood‑related.
Why it matters
The company says the upcoming presentation will provide investors with the first human evidence of its multiplexed mRNA approach, which could affect expectations for the drug’s future development and valuation.
Key facts
- 1Twelve heavily pre‑treated multiple myeloma patients have received mRNA‑2808 in the ongoing Phase 1/2 MyEngage trial. stocktitan.net
- 2Four confirmed responses were observed among 11 response‑evaluable patients, including two very good partial responses and two partial responses. tipranks.com
- 3No dose‑limiting toxicities or treatment‑related serious adverse events were seen. finanznachrichten.de
- 4Cytokine release syndrome occurred in five patients, all classified as Grade 1. tipranks.com
- 5Grade 3 or higher treatment‑related adverse events were reported in 41.7% of patients, primarily hematologic. finanznachrichten.de
- 6The data will be presented orally at the 68th ASH Annual Meeting in New Orleans, December 12‑15 2026. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.